[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"women-health\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:women-health":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,82,109,130,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100644875","remote-virtual-inspiration-vitality-and-energy-100644875",false,"NCT07675681","REmote Virtual Inspiration: Vitality and Energy","Improving Cardiometabolic Health With Meditative Movement in Mobility Impaired Women","REVIVE","Inclusion Criteria:\n\n* Self-identify as a woman.\n* Age 35-64 years.\n* Mobility impairment lasting at least 1 year.\n* Regular use of a mobility aid (e.g., wheelchair, scooter, walker, cane, crutches, or other assistive device).\n* Community dwelling.\n* Able to demonstrate sufficient upper-extremity mobility to participate in seated Tai Chi\u002FQigong activities.\n* Access to a smartphone, tablet, or computer with internet access.\n* Willing to wear a study-provided wearable device and complete study assessments.\n* Reside in the United States.\n* Waist circumference ≥ 33 inches (84 cm).\n* Perceived Stress Scale (PSS) score ≥ 15.\n* Insomnia Severity Index (ISI) score ≥ 8.\n* Emotional eating indicated by a score \\\u003C 3 on the Mindful Eating Questionnaire (MEQ) Emotional Response subscale.\n* Able to understand written and spoken English.\n* Able to provide informed consent.\n* Able to provide healthcare provider approval for participation.\n\nExclusion Criteria:\n\n* Medical conditions that would make participation unsafe, as determined during screening.\n* Inability to safely perform seated upper-body movements.\n* Current participation in a structured Tai Chi, Qigong, or similar meditative movement program.\n* Pregnancy, lactation, or plans to become pregnant during the study period.\n* Cognitive, visual, auditory, or other impairments that would preclude completion of study procedures.\n* Implanted cardiac devices or implanted electronic devices that interfere with physiologic measurements.\n* Severe arrhythmia, left ventricular assist device (LVAD), or other conditions that interfere with heart rate variability assessment.\n* Use of sleep medications three or more times per week.\n* Medical conditions or medications that substantially affect autonomic nervous system activity, sleep, or stress-related outcomes.\n* Uncontrolled cardiovascular, neurological, psychiatric, or other serious medical conditions that would preclude safe participation.","FEMALE","35 Years","64 Years",{"count":21,"type":22},280,"ESTIMATED","INTERVENTIONAL",[25],"NA","REVIVE is a randomized controlled trial designed to evaluate the effects of a remotely delivered seated Tai Chi\u002FQigong (TCQ) intervention on cardiometabolic health, stress, sleep, and psychological well-being among women with mobility impairments.\n\nWomen with mobility impairments experience higher rates of obesity, cardiometabolic disease, chronic stress, sleep disturbances, and mental health concerns compared with women without disabilities. Limited access to accessible physical activity programs and barriers to participation in traditional exercise interventions contribute to these health disparities. Tai Chi and Qigong are gentle mind-body practices that may improve physical and psychological health through movement, breathing, and mindfulness techniques and can be adapted for individuals with limited mobility.\n\nParticipants will be randomized to either a seated Tai Chi\u002FQigong intervention or a health education video control condition. During the 12-week intervention phase, participants will receive daily video-based content delivered remotely. Participants assigned to the Tai Chi\u002FQigong group will engage in seated meditative movement practices, while participants assigned to the control group will receive health and wellness education videos unrelated to physical activity or nutrition behavior change.\n\nOutcomes will be assessed remotely at baseline, post-intervention, and follow-up. Primary outcomes include waist circumference and indicators of physiological stress regulation, including heart rate variability and salivary cortisol. Secondary outcomes include perceived stress, emotion regulation, depression, anxiety, emotional eating, sleep quality, and sleep disturbance. Additional measures collected through wearable technology, sleep diaries, questionnaires, and biological samples will be used to examine potential behavioral, psychological, and physiological mechanisms underlying intervention effects.\n\nThe findings from this study will contribute to the development of accessible, scalable, and evidence-based health promotion interventions designed to improve cardiometabolic health and overall well-being among women with mobility impairments.",[28,29,30,31,32],"Implementation Science","Women Health","Disability Physical","Meditation","Tai Chi",[34,35,36,37,38,39],"Mobility Impairment","Tai Chi\u002FQigong","Cardiometabolic Health","Women with Disabilities","Stress Regulation","Sleep Health","RECRUITING","2026-06-23",{"date":43,"type":44},"2026-06-30","ACTUAL",{"date":46,"type":22},"2026-07",{"date":48,"type":22},"2030-08",{"name":50,"class":51},"Arizona State University","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":17,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":52},"100626857","efficacy-and-safety-of-shatavari-root-extract-in-womens-sexual-wellness-100626857","NCT07441083","Efficacy and Safety of Shatavari Root Extract in Women's Sexual Wellness","Efficacy and Safety of Shatavari (Asparagus Racemosus) Root Extract in Women's Sexual Wellness: A Prospective, Randomized, Double-Blind, Two-Arm, Parallel, Placebo-Controlled Study","Inclusion Criteria:\n\n1. Women between 20 to 50 years of age.\n2. Sexually active, attempting sexual activity, or experiencing concerns related to sexual desire or function, with a partner and have a FSFI total score ≤ 26.55.\n3. Have a PSS-10 score of ≥ 14 at screening.\n4. Women presenting with signs and symptoms suggestive of stress (e.g., difficulty, concentrating, physical exhaustion, anxiety, restlessness, insomnia, headache, fatigue, loss of appetite, worry, sweating, mental confusion, etc.).\n5. Participants who are reliable, honest, compliant, and agree to co operate with all trial evaluations as well as to be able to perform them as per investigator's opinion.\n6. Participants having sufficient understanding to communicate effectively with the investigator and are willing to discuss their sexual functioning with the investigative staff.\n7. Able to read and write in English or any other vernacular language.\n8. No plan to commence new treatments over the study period.\n9. Must have the ability and willingness to sign a written informed consent and to comply with all study procedures.\n\nExclusion Criteria:\n\n1. Participants taking any form of herbal extract in the last 3 months before study entry.\n2. Participants with hormonal imbalance including PCOS, and symptoms of perimenopause and menopause\n3. Participants who are on hormone replacement therapy (HRT) for more than 3 months.\n4. Participants with any active medical, surgical, or gynaecological problems.\n5. Participants with a history of alcohol, tobacco dependence, or any other substance abuse\n6. Participants with clinically relevant cardiovascular, gastrointestinal, hepatic, neurologic, endocrine, haematologic or other major systemic diseases making implementation of the protocol or other interpretation of the study result difficult.\n7. Participants with mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.\n8. Participants with demonstrated inability to comply with the study procedures, including poor compliance.\n9. Participants with inability to attend follow-up visits.\n10. Patients with known hypersensitivity to Shatavari, or any of the ingredients of study interventions.\n11. Patients who had participated in other clinical trials during the previous 3 months.\n12. Patients who have any clinical condition, according to the investigator who does not allow safe fulfilment of clinical trial protocol.",true,"20 Years","50 Years",{"count":64,"type":22},60,[25],"This randomized, double-blind, placebo-controlled clinical study is designed to evaluate the efficacy and safety of a standardized Shatavari (Asparagus racemosus) root extract (SRI-81) in improving women's sexual wellness. Sexual wellness is assessed as a multidimensional construct encompassing sexual function, sexual distress, sexual satisfaction, perceived stress, quality of life, and physiological stress markers. Participants will receive either Shatavari root extract or placebo for 12 weeks, with assessments conducted at baseline and follow-up visits.",[68,29],"Sexual Wellness",[70,71],"dietary supplement","shatavari","2026-04-22",{"date":74,"type":44},"2026-04-27",{"date":76,"type":22},"2026-04-29",{"date":78,"type":22},"2026-08-15",{"name":80,"class":81},"SF Research Institute, Inc.","NETWORK",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":60,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":52},"100626858","efficacy-and-safety-of-shatavari-root-extract-for-premenstrual-syndrome-in-women-100626858","NCT07441096","Efficacy and Safety of Shatavari Root Extract for Premenstrual Syndrome in Women","Efficacy and Safety of Shatavari (Asparagus Racemosus) Root Extract for the Treatment of Premenstrual Syndrome Symptoms in Women: A Randomized, Double-Blind, Two-Arm, Parallel, Placebo-Controlled Study","Inclusion Criteria:\n\n1. Healthy women aged 18-40 years with intact uterus and ovaries.\n2. Females with complaints of experiencing mild to moderate PMS confirmed by one baseline cycle using the DRSP.\n3. PSST sores consistent with PMS and not meeting criteria for severe PMS or PMDD.\n4. Body mass index 18-35 kg\u002Fm2.\n5. Subject who has given written informed consent to participate in the study and understand the nature of the study.\n6. Able to read and write in English or any other vernacular language.\n7. No plan to commence new treatments over the study period.\n8. Must have the ability and willingness to sign an informed consent and to comply with all study procedures.\n\nExclusion Criteria:\n\n* 1\\. Participants taking any form of herbal extract in the last 3 months before study entry. 2. Participants who are on hormone replacement therapy (HRT) for more than 3 months. 3. Participants who are pregnant. 4. Participants with irregular menstrual cycles in the past 12 months (cycle length variability \\>7 days), ≥2 missed cycles in the past 12 months, or amenorrhea ≥60 days. 5. Participants with Present active medical, surgical, and gynaecological problems. 6. Participants with a history of alcohol, tobacco dependence, or any substance abuse. 7. Participants who had undergone bilateral ovariectomy 8. Participants with history of breast or cervical carcinoma 9. Participants who taking medication that affect bone metabolism, including glucocorticoid, anticonvulsant, and methotrexate. 10. Participants with clinically relevant cardiovascular, gastrointestinal, hepatic, neurologic, endocrine, haematologic or other major systemic diseases making implementation of the protocol or other interpretation of the study results difficult. 11. Participants with mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study. 12. Participants with demonstrated inability to comply with study procedures or follow-up visits. 13. Participants with inability to attend follow-up visit 14. Participants with any other medical condition (for example uncontrolled infection) that may, in the opinion of the Investigator, interfere with the study objective. 15. Patients who had participated in other clinical trials during the previous 3 months. 16. Patients who have any clinical condition, according to the investigator who does not allow safe fulfilment of clinical trial protocol.","18 Years","40 Years",{"count":64,"type":22},[25],"Premenstrual syndrome (PMS) is a common condition that affects women of reproductive age and is associated with emotional, physical, and behavioral symptoms such as mood swings, irritability, stress, sleep problems, fatigue, and abdominal discomfort. These symptoms typically occur during the days leading up to menstruation and may interfere with daily activities and overall quality of life.\n\nThis study is designed to evaluate the efficacy and safety of Shatavari (Asparagus racemosus) root extract compared with placebo in women with mild to moderate PMS. Eligible participants will be randomly assigned to receive either Shatavari root extract (300 mg) or an identical placebo capsule once daily for 12 weeks. The study will assess changes in PMS symptoms, stress levels, sleep quality, and quality of life using validated questionnaires, along with measurements of salivary cortisol. Safety will be evaluated through clinical laboratory tests and monitoring of adverse events throughout the study.",[95,29],"Premenstrual Syndrome",[97,98,99],"PMS","Shatavari","Asparagus racemosus","NOT_YET_RECRUITING","2026-02-28",{"date":103,"type":44},"2026-03-03",{"date":105,"type":22},"2026-03-20",{"date":107,"type":22},"2026-07-08",{"name":80,"class":81},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":60,"sex":17,"minAge":90,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":52},"100626859","shatavari-root-extract-for-perimenopausal-symptoms-100626859","NCT07441109","Shatavari Root Extract for Perimenopausal Symptoms","Efficacy and Safety of Shatavari (Asparagus Racemosus) Root Extract for Treatment of Perimenopausal Symptoms in Women: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study","Inclusion Criteria:\n\n1. Menopausal women aged \\>40 to 45 years with intact uterus and ovaries.\n2. Participants who complained of irregular menstrual cycle in the past 12 months, with a forward or postpone of a cycle more 7 days. At least 2 cycles were missing during the past 12 months or reported menopause for at least 60 days.\n3. Females with complaints of at least two of the menopausal symptoms, e.g., hot flashes, night sweats, mood swings, sleep disturbance, breast tenderness\n4. Body mass index 18-35 kg\u002Fm2\n5. Subject who has given written informed consent to participate in the study and understand the nature of the study.\n6. Able to read and write in English or any other vernacular language.\n7. No plan to commence new treatments over the study period.\n8. Must have the ability and willingness to si\n\nExclusion Criteria:\n\n1. Participants taking any form of herbal extract in the last 3 months before study entry.\n2. Participants who are on hormone replacement therapy (HRT) for more than 3 months.\n3. Participants who are pregnant.\n4. Participants with present active medical, surgical, and gynaecological problems.\n5. Participants with a history of alcohol, tobacco dependence, or any substance abuse.\n6. Participants who had undergone bilateral ovariectomy\n7. Participants with history of breast or cervical carcinoma\n8. Participants who taking medication that affect bone metabolism, including glucocorticoid, anticonvulsant, and methotrexate.\n9. Participants with clinically relevant cardiovascular, gastrointestinal, hepatic, neurologic, endocrine, haematologic or other major systemic diseases making implementation of the protocol or other interpretation of the study result difficult.\n10. Participants with mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.\n11. Participants with evidence of demonstrated inability to follow study protocols or attend follow-up visits, including poor compliance.\n12. Participants with demonstrated inability to follow study protocols or attend follow-up visit\n13. Participants with inability to attend follow-up visit\n14. Participants with any other medical condition (for example uncontrolled infection) that may, in the opinion of the Investigator, interfere with the study objective.\n15. Patients who had participated in other clinical trials during the previous 3 months.\n16. Patients who have any clinical condition, according to the investigator, who does not allow safe fulfilment of clinical trial protocol.","45 Years",{"count":64,"type":22},[25],"This randomized, double-blind, placebo-controlled clinical study evaluates the efficacy and safety of a standardized Shatavari (Asparagus racemosus) root extract in women experiencing perimenopausal symptoms. Participants will receive either Shatavari root extract or a matched placebo for 12 weeks. Efficacy will be assessed using validated menopause-specific symptom, quality-of-life, stress, mood, and sleep questionnaires, along with physiological stress markers. Safety will be evaluated through laboratory assessments and adverse event monitoring.",[121,29],"Perimenopause",[98,123],"Dietary Supplement",{"date":103,"type":44},{"date":126,"type":22},"2026-03-11",{"date":128,"type":22},"2026-06-29",{"name":80,"class":81},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":60,"sex":17,"minAge":138,"maxAge":62,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":52},"100579564","asian-mediterranean-diet-and-womens-health-100579564","NCT06825936","Asian-Mediterranean Diet and Women's Health","Asian-Mediterranean Diet and Women's Health: A Randomized Controlled Trial (A+ MEAL Study)","A+ MEAL","Inclusion Criteria:\n\nSubjects must meet all of the inclusion criteria for participation:\n\n1. Females aged 21-50 years\n2. Chinese ethnicity\n3. Singapore citizens, permanent residents, or long-term pass holders\n4. Is able to complete questionnaires in English\n5. BMI ≥ 23.0 kg\u002Fm2 but \\\u003C 37.5 kg\u002Fm2\n6. Not planning to conceive in the next 12 months from enrolment (you will be asked to withdraw once you conceive during the study period)\n7. Not planning to leave Singapore for more than 2 consecutive calendar weeks (10 working days) in the next six months from enrolment\n8. Not currently pregnant or breastfeeding\n9. Not currently smoking\n10. Without history of major chronic diseases (e.g., cancer, diabetes, cardiovascular diseases, chronic kidney disease), major infectious diseases (e.g. hepatitis B, HIV), severe gastrointestinal disorders (e.g. colitis or inflammation of the bowel, celiac disease, chronic gastritis) and major medical procedures\u002Fsurgeries related to these conditions\n11. Without major mental health condition\n12. Without known food allergies, especially to nuts and seafood.\n13. Not on any special diets or having dietary restrictions (e.g. vegetarians, vegans, ketogenic, Kosher diet)\n14. Not currently and will not be enrolled in another interventional study or studies that may affect weight, cardiometabolic health, gut, or brain health in the next six months from enrolment\n\nExclusion Criteria:\n\nSubjects not meeting any of the above inclusion criteria will be excluded from participation.\n\nAdditional Exclusion Criteria for MRI procedure only:\n\ni. Shoulder width ≥60cm ii. Has any medical implants or foreign bodies, particularly related to heart, brain, or eye implants, including but not limited to pacemakers, artificial heart valves, implantable cardioverter defibrillators, ventricular assist devices, brain stimulation devices, intrauterine devices, and breast biopsies (if any implant or tissue marker has been placed) iii. History of head injury or trauma with loss of consciousness iv. Metallic dental braces or dental implants v. Having claustrophobia vi. Drinks more than 30 units of alcohol per week (1 unit = 25mL 40% spirit, 1 can of beer = 2 units, 1 standard glass of wine = 2 units)","21 Years",{"count":140,"type":22},300,[25],"Given the escalating high burdens of overeight and obesity, and related commobidies in Asia, Asian women with overweight\u002Fobesity is an important group for targeted intervention in promoting health and wellbeing. A study focused on Asian women at reproductive or early post-menopausal age can inform effective strategies for promoting healthy diet and lifetyle and for optimizing health not only among these women but also for their children and partners.\n\nThe Mediterranean diet has beneficial effects on cardiometabolic and reproductive health. So far, evidence on the Mediterranean diet and its health benefits mostly come from Western populations. Studies evaluating health effects of Mediterranean diet in Asian population are scant.\n\nThis study aims to investigate the beneficial effects of a healthy, Mediterranean-inspired localized diet (i.e., Asian-Mediterranean diet) on women's health, such as cardiometabolic health with potential mechanisms through modulating gut and brain health.",[144,145,29],"Cardiometabolic Risk Factors","Cardiometabolic Conditions",[147,148,149,150],"Cardiometabolic health","Mediterranean diet","Women health","Cardiometabolic risk factors","2025-03-10",{"date":153,"type":44},"2025-03-12",{"date":155,"type":44},"2025-02-10",{"date":157,"type":22},"2026-10",{"name":159,"class":51},"Global Centre for Asian Women's Health",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":60,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":180,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":52},"100568305","impact-of-menstrual-cycle-based-resistance-training-on-neuromuscular-performance-in-female-athletes-100568305","NCT06679491","Impact of Menstrual Cycle-Based Resistance Training on Neuromuscular Performance in Female Athletes","Effects of Menstrual Cycle-based Undulating Periodized Resistance Training in Women's Neuromuscular Abilities","MENSES","Inclusion Criteria:\n\n* Female athletes with natural menstrual cycles (eumenorrheic): Participants must have regular menstrual cycles lasting between 21 and 35 days, with at least 9 cycles per year.\n* Women using a low-dose monophasic estrogen-progestin oral contraceptive.\n* Age 18 or older: Participants must be legal adults.\n* Body Mass Index (BMI) between 18 and 30 kg\u002Fm².\n* No medical contraindications to high-level physical training or exercise.\n* Physically active: Engages in at least 3 hours of physical activity per week.\n* Informed consent: Provides written, informed consent to participate in the study.\n* Affiliation with a social security system (if applicable by local regulations).\n\nExclusion Criteria:\n\n\\-",{"count":64,"type":22},[25],"The goal of this clinical trial is to assess the impact of menstrual cycle-based resistance training on neuromuscular function in female athletes.\n\nThe primary questions it aims to answer are :\n\n* Does varying resistance training intensity according to menstrual phases improve maximal knee extensor strength?\n* How do different training protocols affect voluntary activation, rate of force development, muscle stiffness, and vertical jump height?\n\nResearchers will compare natural menstrual cycle groups with an oral contraceptive control group to determine if menstrual phase-specific training influences neuromuscular adaptations.\n\nParticipants will:\n\n* Undergo 2 weekly resistance training sessions over 13 weeks with intensity adjustments based on menstrual phase\n* Complete periodic neuromuscular assessments across three menstrual phases: early follicular, late follicular, and mid-luteal before and after resistance training intervention",[172,173,174,175,29,176,177,178,179],"Menstrual Cycle","Resistance Training","Neuromuscular Function","Female Athlete","Oral Contraceptive Pill","Muscle Strenght","Hormones","Periodized Training",[172,181,182,183,184,178,185,186],"Resistance training","Periodized training","neuromuscular function","Female athlete","oral contraceptive pill","women health","2024-11-05",{"date":189,"type":44},"2024-11-07",{"date":191,"type":22},"2024-11-01",{"date":193,"type":22},"2027-12-31",{"name":195,"class":51},"Universite de La Reunion"]